Metamizol Stada

Metamizole sodium, the active ingredient in Metamizol Stada, is a pyrazolone analgesic presented as an oral formulation for oral use. It is employed to relieve mild to moderate pain, reduce fever, and manage postoperative and visceral pain in adult patients. The product meets European Union pharmaceutical quality standards and is classified as prescription‑only.

GNH USA supplies Metamizol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulatory support, customs clearance assistance, and reliable logistics where required.

Metamizol Stada, a pyrazolone analgesic, is used in several pain‑related and febrile conditions.

- Mild to moderate pain: provides analgesia for everyday aches and musculoskeletal discomfort. - Fever: reduces elevated body temperature in acute infectious or inflammatory states. - Post‑operative pain: helps control pain after surgical procedures. - Colic and visceral pain: alleviates spasm‑related discomfort in the gastrointestinal tract. - Cancer‑related pain: used as part of multimodal analgesia for tumor‑associated pain.

Metamizol Stada may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal upset occurring shortly after dosing. - Dizziness or light‑headedness: transient sensation of unsteadiness. - Skin rash or itching: mild dermatologic irritation. - Headache: occasional throbbing pain in the head region.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially leading to infection. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions. - Anaphylaxis: rapid onset of allergic symptoms including airway compromise. - Hepatic or renal impairment: abnormal liver enzymes or kidney function tests.

Before initiating therapy with Metamizol Stada, several safety considerations should be observed. - Baseline blood count: obtain complete blood count to detect pre‑existing cytopenias. - Renal or hepatic dysfunction: adjust use or monitor closely in patients with organ impairment. - Hypotension risk: be cautious in individuals prone to low blood pressure. - Known hypersensitivity: avoid in patients with documented allergy to pyrazolones. - Concomitant immunosuppressants: monitor for additive bone‑marrow suppression. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metamizol Stada can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding due to additive anticoagulant effect. - Methotrexate: heightened toxicity, especially to bone marrow and liver. - Cyclosporine: enhanced nephrotoxic potential when combined.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation and ulcer risk. - Diuretics: possible potentiation of hypotensive effects.